We genotyped 2,861 cases of primary biliary cirrhosis (PBC) from the UK PBC Consortium and 8,514 UK population controls across 196,524 variants within 186 known autoimmune risk loci. We identified 3 loci newly associated with PBC (at P < 5 × 10 −8 ), increasing the number of known susceptibility loci to 25. The most associated variant at 19p12 is a low-frequency nonsynonymous SNP in TYK2, further implicating JAK-STAT and cytokine signaling in disease pathogenesis. An additional five loci contained nonsynonymous variants in high linkage disequilibrium (LD; r 2 > 0.8) with the most associated variant at the locus. We found multiple independent common, low-frequency and rare variant association signals at five loci. Of the 26 independent non-human leukocyte antigen (HLA) signals tagged on the Immunochip, 15 have SNPs in B-lymphoblastoid open chromatin regions in high LD (r 2 > 0.8) with the most associated variant. This study shows how data from dense fine-mapping arrays coupled with functional genomic data can be used to identify candidate causal variants for functional follow-up.
Primary biliary cirrhosis is characterized by the immune-mediated destruction of intrahepatic bile ducts, resulting in chronic cholangitis, liver fibrosis and, ultimately, cirrhosis 1 . With a UK prevalence of 35:100,000, which rises to 94:100,000 in women over 40 years of age, it is the most common autoimmune liver disorder 1, 2 . Family-based studies indicate a substantial genetic component to PBC susceptibility, with a sibling relative risk of ~10.5 in the UK 3 . Genome-wide association studies (GWAS) have identified 22 PBC risk loci and have highlighted the role of nuclear factor (NF)-κB signaling, T-cell differentiation, and Toll-like receptor and tumor necrosis factor signaling in disease pathogenesis [4] [5] [6] .
Sixteen of these loci are also associated with other immune-mediated diseases, such as multiple sclerosis, celiac disease and type 1 diabetes (T1D), shedding light on the involvement of common genes and pathways across these diseases 7 . Despite these advances, the specific causal variant at many of these loci remains unknown.
To better define risk variants and identify additional susceptibility loci, we performed a fine-mapping and association study using a cohort of 2,861 cases from the UK PBC Consortium and 8,514 UK population controls from the 1958 British Birth Cohort and National Blood Service. All samples were genotyped on the Immunochip, an Illumina Infinium array containing 196,524 variants (718 small insertions and/or deletions and 195,806 SNPs) across 186 known autoimmunity risk loci. SNPs were derived from population-based sequencing projects such as the 1000 Genomes Project and autoimmune disease resequencing efforts 8, 9 . Compared to GWAS arrays, the Immunochip has increased marker density within known autoimmunity-associated loci, increasing the power to detect PBC associations within these selected key candidate genes and providing a powerful means of fine mapping known PBC loci, as causal variants are more likely to be directly genotyped.
After quality control (Online Methods), data at 143,020 polymorphic SNPs were available across 2,861 cases and 8,514 controls. (Supplementary Figs. 1-6 and Supplementary Tables 1 and 2 ). An additional 94,559 SNPs in the Immunochip fine-mapping regions were imputed using genotypes from the 1000 Genomes Project June 2011 release (Online Methods). The inflation factor inferred from 2,258 SNPs not associated with autoimmune disease showed only modest inflation (λ = 1.096; Online Methods) similar to that reported in our previous GWAS for PBC 6 .
Of the 22 known PBC risk loci, 16 had associations that reached genome-wide significance (P < 5 × 10 −8 ; Fig. 1 and Supplementary Fig. 7) , Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis 1 1 3 8 VOLUME 44 | NUMBER 10 | OCTOBER 2012 Nature GeNetics l e t t e r S and 4 showed nominal evidence of association (5 × 10 −8 < P < 5 × 10 −4 ; Supplementary  Table 3 ). Two PBC-associated loci, 14q32 and 19q13, were not included on the Immunochip, as the array was designed before the publication of the most recent PBC GWAS 6 . At 12 of the loci that associated with genome-wide significance, the most associated SNP was different from the one previously reported at that locus ( Supplementary Table 3 ). There was little difference in the effect size estimates of the GWAS-identified tagging SNP and the most strongly associated Immunochip SNP ( Supplementary Fig. 8 ), although this may be due to a large proportion of overlapping samples between the two studies (Online Methods).
Stepwise conditional regression 10 revealed multiple independent signals at five loci, with 16p13 harboring three and 3q25 four such associations ( Table 1) . At the 16p13 locus, the third independent signal, rs80073729, is a rare SNP (minor allele frequency (MAF) < 0.5%) that was recently associated with celiac disease 9 . In the same study 9 , multiple independent signals were also identified at 3q25, although rs80014155, a rare SNP that best tags the fourth most significant independent PBC association at this locus, was not among them. These results suggest that resequencing hundreds or thousands of cases across known GWAS loci will be a powerful means of identifying additional independent risk alleles. It is likely that these two rare SNP associations would have been missed using standard GWAS arrays, because of poor tagging, unless they were directly genotyped. As these are rare SNPs, further replication in large independent cohorts will be required to confirm their associations. Haplotype association analysis at loci with multiple independent signals identified similar effect size estimates, suggesting that the causal variant at each locus is among or is highly correlated with genotyped SNPs ( Supplementary Table 4 ). These additional independent association signals thus yield a more complete understanding of the genetic architecture of PBC and enable more informative genotype-based recall studies to be conducted.
Variants at three loci not previously reported to be associated with PBC reached the genome-wide significance threshold ( Table 1) . The most significant association at 19p12, rs34536443 (odds ratio (OR) = 1.91; P = 1.24 × 10 −12 ), is a low-frequency (1% ≤ MAF < 5%) nonsynonymous SNP in the TYK2 gene (encoding tyrosine kinase 2), which was previously shown to associate with multiple sclerosis 11 . The locus has also been associated with T1D 12 , psoriasis 13 and Crohn's disease 14 , although rs34536443 was not genotyped as part of these studies. For T1D and psoriasis, the strongest associations were with common SNPs that reside on the same haplotype (rs2304256 (r 2 = 0.06, D′ = 0.9) and rs280519 (r 2 = 0.03, D′ = 1)). The most associated SNP in Crohn's disease (rs12720356), which is the second most significant psoriasis signal, is independent of rs34536443 (r 2 = 0, D′ = 0.003). The 12q24 locus has been associated with celiac disease 9,15 , rheumatoid arthritis 16 and T1D 17 ; however, it was a nonsynonymous SNP in SH2B3, rs3184504 (OR = 1.19; P = 1.11 × 10 −8 ), rather than the most significant SNP in this study, rs11065979 (OR = 1.2; P = 2.87 × 10 −9 ), that was most strongly associated. These two SNPs are in high LD (r 2 = 0.81), and further studies are required to identify the causal variant underlying the PBC association signal at this locus. The most associated SNP in the 17q21 region, rs17564829 (OR = 1.25; P = 2.15 × 10 −9 ), is located in MAPT, a gene that has been associated with cognitive symptoms in Parkinson's disease. Although cognitive symptoms are a major part of the symptom complex associated with PBC, it remains to be determined whether (i) the true causal variant at the locus has its functional effect through MAPT and (ii) this functional effect then results in cognitive changes in individuals with PBC.
Both TYK2 and SH2B3 are involved in the production of cytokines, adding to the evidence that cytokine imbalance has a role in PBC and other autoimmune diseases 18, 19 . TYK2 is a member of the Janus kinase family, which transduce cytokine signals by phosphorylating STAT transcription factors. Heterozygotes for rs34536443 have been shown to have significantly reduced TYK2 activity, which promotes the secretion of T helper type 2 (T H 2) cytokines 20 . Carriers of the rs3184504[A] risk allele in SH2B3 show a moderate increase in production of cytokines and stronger activation of the NOD2 recognition pathway compared to carriers of the rs3184504[G] allele 21 , suggesting a possible role for the risk allele in helping to prevent bacterial infection.
Candidate gene studies have implicated several HLA-DR alleles in PBC susceptibility, particularly the HLA-DRB1*08 allele [22] [23] [24] [25] . To further characterize HLA risk variants, the classical HLA alleles (at HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-DQB1 and HLA-DRB1) were imputed from genotyped SNPs in the major histocompatibility complex (MHC) region 26, 27 (Online Methods). Fourteen HLA alleles reached genome-wide significance, and conditional analysis clustered these associations into four independent signals (Supplementary Fig. 9 and Supplementary Table 5 ). The most significant association was with the HLA-DQA1*0401 allele (OR = 3.06; P = 5.9 × 10 −45 ), which forms a haplotype with two other HLA class 2 alleles (HLA-DQB1*0402 and HLA-DRB1*0801) and is an established PBC risk locus [22] [23] [24] [25] . The second and third most significant clusters, rs11065979  rs17564829  rs34536443  rs3024921  rs7574865  rs2366643  rs62270414  rs668988  rs80014155  rs35188261  rs3807307  rs1800693  rs11064157  rs1646019 rs12708715 rs80073729 Figure 1 Manhattan plot and list of PBC risk loci that reached genome-wide significance across the Immunochip. New risk loci are highlighted in blue. Loci with more than one independent signal are highlighted in red. The horizontal red line indicates the genome-wide significance threshold of P = 5 × 10 −8 . The peak on chromosome 6 is the HLA region.
npg l e t t e r S HLA-DQB1*0602 (OR = 0.64; P = 2.32 × 10 −15 ) and HLA-DQB1*0301 (OR = 0.70; P = 6.48 × 10 −14 ), both have protective effects, confirming previous studies showing suggestive associations between these loci and PBC susceptibility 22, 23 . The fourth most associated cluster, HLA-DRB1*0404 (OR = 1.57; P = 1.22 × 10 −9 ), has not previously been associated with PBC. The variance in liability explained by the 26 independent SNPs and 4 HLA types is 4.9% and 1.4%, respectively, which together account for 16.2% of the total PBC heritability of liability of 0.39 (Online Methods).
To identify candidate causal variants, we searched for nonsynonymous variants in high LD (r 2 > 0.8) with the most associated variants at each PBC risk locus. We found 39 such variants (of which 13 were directly genotyped) within 7 risk loci ( Table 1 and Supplementary  Table 6 ), including 2 variants at 2 of the loci newly associated with PBC in this study, TYK2 and SH2B3. Functional follow-up studies are needed before these nonsynonymous variants can be confirmed as the causal variants at these loci. As variation in gene expression is also likely to influence PBC risk, we evaluated the extent to which the most associated SNP at each locus tags expression quantitative trait loci (eQTLs) or regions of open chromatin. Regions of open chromatin are associated with gene regulatory elements, including promoters, enhancers, silencers, insulators and locus control regions. Known eQTLs were collated from the University of Chicago eQTL Browser (see URLs) and from a previous study 28 . Open chromatin regions in a range of cell lines were identified as part of the Encyclopedia of DNA Elements (ENCODE) Project 29, 30 using DNase I hypersensitive site sequencing (DNase-seq) and formaldehyde-assisted isolation of regulatory elements sequencing (FAIRE-seq).
Of the 26 independent non-HLA genome-wide significant SNPs identified in this study, 15 had r 2 of >0.8 with SNPs in DNase-seq or FAIRE-seq peaks in a B-lymphoblastoid cell line, and 7 were also significant eQTLs in the same cell line ( npg l e t t e r S that for all other cell lines, we began by grouping SNPs into independent loci. We sequentially identified the most associated SNP not already assigned to a locus and assigned this SNP and others in weak LD with it (r 2 > 0.1) to a new locus. We then calculated an enrichment score, E (Online Methods), using only candidate causal variants (r 2 > 0.8 with the most associated SNP in each locus) across all currently assigned loci. Considering only loci where the most associated SNP achieved genome-wide significance (N = 21, excluding the HLA locus, SNPs outside Immunochip fine-mapping regions and SNPs with MAF of <5%), Gm12878 had the highest enrichment score compared with the other cell lines, although the difference in enrichment was not quite significant (P = 0.068; Online Methods) ( Fig. 2) . Inability to correctly account for LD between associated SNPs can bias the calculated degree of enrichment ( Supplementary Fig. 10 ). Our enrichment analysis protocol can be applied to other functional annotations and other disease phenotypes and is well powered for traits with many associations that reach genome-wide significance.
In summary, we have used dense genotyping across autoimmune disease-associated loci to better define the genetic architecture of known PBC risk loci. We have identified additional independent associations at genome-wide significance at five loci and have identified potentially causal protein-coding and regulatory variants within many disease-associated loci. We also identified 3 new PBC risk loci, bringing the total number of associated loci to 25, and confirmed HLA allele associations by imputing HLA types. Furthermore, we have combined our SNP data with large-scale functional genomics annotations to identify the cell types in which the PBC-associated variants are likely to act.
URLs. University of Chicago eQTL Browser, http://eqtl.uchicago. edu/cgi-bin/gbrowse/eqtl/.
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Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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DNA extraction. DNA was extracted from blood or saliva. Blood samples from PBC cases were extracted by the East Anglian Medical Genetics Service, and saliva samples were collected using an Oragene kit and DNA extracted at Source BioScience Healthcare. DNA samples were plated, normalized and shipped to the Wellcome Trust Sanger Institute for sample quality control analysis.
Genotyping. Samples were genotyped on an Illumina iSelect HD custom genotyping array (Immunochip). All 2,981 cases and 4,537 controls were genotyped at the Wellcome Trust Sanger Institute. An additional 4,433 control samples were genotyped at the Center for Public Health Genomics at the University of Virginia. Genotyping of control samples was coordinated by the Immunochip Consortium for use in several Immunochip projects. The NCBI Build 36 (hg18) map was used (Illumina manifest file Immuno_BeadChip_11419691_B.bpm). Normalized probe intensities were extracted for all samples passing standard laboratory quality control thresholds, and genotypes were called using opti-Call 31 . Genotypes with an individual posterior probability lower than 0.7 were defined as unknown. optiCall was chosen because we found it to be more accurate in calling common and low-frequency variants on Immunochip compared to other established algorithms such as Illuminus 32 and GenoSNP 33 .
Quality control. Sample quality control was performed for each sample set separately. All monomorphic SNPs were removed before quality control. Samples with a call rate lower than 98% and heterozygosity more than 3 s.d. from the mean were excluded. A set of LD-pruned SNPs with MAF of >20% were used to estimate identity by descent (IBD) and ancestry. For each pair of individuals with an estimated IBD of >18.75%, the sample with the lower call rate was removed. Principal-component analysis was used to exclude samples of non-European ancestry 34 (Supplementary Figs. 1-3) . After sample quality control, 2,861 cases and 8,514 controls remained ( Supplementary  Table 1 ). SNPs with MAF of <0.1%, Hardy-Weinberg equilibrium P < 1 × 10 −6 , call rate lower than 98% or significantly different (P < 1 × 10 −5 ) call rate in cases versus controls (or between the two control sets) were excluded. After marker quality control, 143,020 polymorphic SNPs were available for analysis (Supplementary Table 2 ). Statistical methods. Genomic inflation factor. The Immunochip contains 2,258 SNPs that lie in regions associated with bipolar disease. These were used as null markers to estimate the overall inflation of the distribution of association test statistics 35 .
Imputation. Using the 90,977 SNPs from the cleaned Immunochip set that were in fine-mapped regions, additional genotypes were imputed using the 1000 Genomes Project Phase I (interim) June 2011 release reference panel and IMPUTE2 (ref. 36) . Imputation was performed separately in 3 batches of 3,792, 3,792 and 3,791 individuals, with the case-control ratio constant across batches. SNPs with a posterior probability less than 0.9 and those with differential missingness (P < 1 × 10 −5 ) between the three batches were removed, as were those SNPs that failed the same exclusion thresholds used for the original Immunochip quality control analysis. After imputation, a total of 237,619 SNPs were available for analysis.
Association analysis. Case-control association tests were implemented using a standard 1-degree-of-freedom Cochran-Armitage test for trend in PLINK v1.07 (ref. 37) . Secondary associations were identified using stepwise logistic regression analysis conditioning on the allelic dosage of the primary signal in each significantly associated locus. The process was repeated, conditioning on all independent genome-wide significant SNPs, until all genome-wide significant signals were accounted for 10 . Haplotype association analysis was performed in PLINK using logistic regression. Cluster plots for all SNPs associated at P < 5 × 10 −6 were manually checked using Evoker 38 , and poorly called SNPs were removed from further study (Supplementary Fig. 11) .
HLA imputation. Imputation of six classical HLA alleles (class 1: HLA-A, HLA-B and HLA-C; class 2: HLA-DQA1, HLA-DQB1 and HLA-DRB1) was performed using the prediction algorithm proposed by Leslie et al. 26 and implemented in the program HLA*IMP 27 . Case-control association was performed on HLA allele posterior probabilities generated from HLA*IMP using logistic regression to account for genotype uncertainty after imputation. Pairwise conditional logistic regression was used to identify independent association signals among the 21 HLA alleles that reached P < 0.0001.
Heritability explained. The heritability explained by the 26 independent genome-wide significant SNPs and 4 HLA alleles was estimated using a liability threshold model 39, 40 assuming a disease prevalence of 40:100,000, logadditive risk and a sibling relative risk ratio of 10.5 (ref. 3) . eQTL analysis. eQTLs within genome-wide significant loci were collated from the University of Chicago eQTL Browser (see URLs) and a study by Gaffney et al. 28 . The eQTL Browser contains significant eQTLs that were identified in recent studies across multiple cell lines and populations, and Gaffney et al. reanalyzed gene expression data from 210 lymphoblastoid cell lines using a total of 13.6 million SNPs from the 1000 Genomes Project. For more details, see ref. 28 
and references listed on the Chicago eQTL Browser web site (see URLs).
Enrichment of open chromatin regions. The ENCODE project annotated regions of open chromatin using two techniques: DNase-seq (16 different cell lines) and FAIRE-seq (10 different cell lines) 29, 30 . Both methods isolate nucleosome-depleted regions of DNA and map reads from next-generation sequencing to determine their location. The overlap of peaks between the two assays ranges from 30-40%, depending on the cell type, and regions identified uniquely by DNase-seq or FAIRE-seq often represent relevant biological processes 29 . Positions of discrete DNase-seq and FAIRE-seq peaks were estimated from the base overlap signal (BOS) at each base pair 29 . We quantified the evidence for the open chromatin peaks using a Poisson distribution where λ equals the mean BOS across all Immunochip SNPs. The relative positions of open chromatin peaks and associated SNPs within significantly associated loci are shown in Supplementary Figure 12 .
For both DNase-seq and FAIRE-seq data, we estimated the amount of enrichment for open chromatin peaks among significant loci across the ENCODE cell lines. SNPs were first grouped into independent loci; we sequentially identified the most associated SNP not already assigned to a locus and assigned this SNP and others in weak LD with it (r 2 > 0.1) to a new locus. After the addition of each new locus, we calculated enrichment (E) npg open chromatin peaks across all cell lines other than the one being evaluated. We then tested the alternative hypothesis that, for a given cell line, the proportion OC loci / OC ichip > OC loci:all cells / OC ichip:all cells using a χ-square test for the difference in proportions.
To ensure that our test was well calibrated under the null hypothesis, we undertook 1,000 permutations, repeating the association and enrichment analyses for each permutation. Comparing the observed level of enrichment at our top 21 loci to the equivalent level from the permutations, we obtained a similar, non-significant empirical P value of 0.073, indicating that our proposed enrichment analysis is well calibrated under the null hypothesis. A 95% confidence interval for E was estimated using the permutations.
